Millennium Management’s LENZ Therapeutics LENZ Stock Holding History

Millennium Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.95M	Buy	869,257 +329,909	+61%	+$4.63M	﹤0.01%	2410
2025 Q4	$8.63M	Buy	+539,348	New	+$15.7M	﹤0.01%	2419
2024 Q1	–	Sell	-12,938	Closed	-$237K	–	6738
2023 Q4	$237K	Sell	12,938 -716	-5%	-$11.8K	﹤0.01%	5087
2023 Q3	$237K	Buy	13,654 +8,465	+163%	+$147K	﹤0.01%	5032
2023 Q2	$94.4K	Sell	5,189 -5,273	-50%	-$105K	﹤0.01%	5338
2023 Q1	$179K	Sell	10,462 -8,587	-45%	-$139K	﹤0.01%	5218
2022 Q4	$443K	Sell	19,049 -31,047	-62%	-$720K	﹤0.01%	4832
2022 Q3	$1.11M	Sell	50,096 -25,083	-33%	-$598K	﹤0.01%	4246
2022 Q2	$1.45M	Buy	75,179 +57,495	+325%	+$1.28M	﹤0.01%	4022
2022 Q1	$631K	Sell	17,684 -417	-2%	-$26.1K	﹤0.01%	4933
2021 Q4	$1.57M	Sell	18,101 -59,206	-77%	-$4.91M	﹤0.01%	3986
2021 Q3	$8.87M	Sell	77,307 -6,955	-8%	-$1.03M	0.01%	2228
2021 Q2	$18.1M	Buy	+84,262	New	+$14.7M	0.01%	1287

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Millennium Management's LENZ Position: Q1 2026 in Review

Millennium Management increased its LENZ Therapeutics (LENZ) stake by 61% in Q1 2026, buying an estimated $4.63M and bringing the position to 869,257 shares worth $7.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Millennium Management first reported a position in LENZ in Q2 2021 and has held it in 13 quarters since. The position peaked at $18.1M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Millennium Management held 869,257 shares of LENZ Therapeutics worth $7.95M as of Q1 2026.
Millennium Management bought 329,909 LENZ Therapeutics shares in Q1 2026, an estimated $4.63M.
LENZ Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2410 holding.
Millennium Management first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 13 quarters since.
Millennium Management's LENZ Therapeutics position peaked at $18.1M in Q2 2021.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.